Patient demographics and characteristics of the study population at baseline.

*Baseline includes all medications used on at least 1 day between informed consent and randomization (inclusive) and on at least 1 day between randomization and the first day of randomized drug intake (inclusive). BMI, body mass index; FEV1, forced expiratory volume in 1 second; LABA, long-acting β-agonist; SABA, short-acting β-agonist; SD, standard deviation.
Patient demographics and characteristics of the study population at baseline.

* 本基线集纳入所有在知情同意至随机分组（含两端日期）期间、以及随机分组至首次随机化给药首日（含两端日期）期间至少使用1天的药物。BMI（body mass index，体重指数）；FEV1（forced expiratory volume in 1 second，一秒用力呼气容积）；LABA（long-acting β-agonist，长效β激动剂）；SABA（short-acting β-agonist，短效β激动剂）；SD（standard deviation，标准差）。
研究人群基线时的人口统计学特征与临床特征。